A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Completed · Phase 2

Conditions studied: Non Small Cell Lung Cancer

In brief

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

Key facts

Study ID

NCT00743938

Run by

Bristol-Myers Squibb

People needed

141

Starts

2009-03-01

Expected to finish

2012-06-01

Last updated by the study team

2015-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG PS of 0 or 1
• Histologically confirmed NSCLC
• Adequate amount of tumor (archived or fresh) for biomarker evaluation
• Received one to two regimens of chemotherapy (with at least one platinum-containing)
• Serum creatinine of less than 1.0 mg/dL or a 24 hour creatinine clearance of greater than 60 mL/min
• Stable control of blood pressure on agents other than calcium channel blockers
• Women of child-bearing potential must avoid pregnancy or maintain adequate contraception
• Must be able to swallow pills and take the medications at the same time every day on an empty stomach

You may not qualify if…

• ECOG PS 2 or greater
• Women unwilling to avoid pregnancy or use adequate contraception
• Symptomatic brain metastases
• Recent history of TIA, CVA, or thrombotic/thromboembolic event (within 6 months)
• History of hemoptysis greater than 10 mL/day
• Significant cardiovascular disease
• Uncontrolled diarrhea, Crohn's disease, ulcerative colitis, or any malabsorptive disease
• History of use of other TKIs
• Uncontrolled hypertension
• HIV+

Where it is running

• Yale University School Of Medicine — New Haven, Connecticut, United States
• Hematology Oncology, P.C. — Stamford, Connecticut, United States
• Mass General Hospital — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Piedmont Hematology Oncology Associates, Pllc — Winston-Salem, North Carolina, United States
• Oregon Health & Science University — Portland, Oregon, United States
• Hema/Oncology Assoc. Of Nepa — Dunmore, Pennsylvania, United States
• Cancer Center Of The Carolinas — Greenville, South Carolina, United States
• Local Institution — Bahía Blanca, Buenos Aires, Argentina
• Local Institution — Buenos Aires, Buenos Aires, Argentina
• Local Institution — La Plata, Buenos Aires, Argentina
• Local Institution — Córdoba, Córdoba Province, Argentina
• Local Institution — La Rioja, La Rioja Province, Argentina
• Local Institution — Montreal, Quebec, Canada
• Local Institution — Sherbrooke, Quebec, Canada
• Local Institution — Lyon, France
• Local Institution — Marseille, France
• Local Institution — Strasbourg, France
• Local Institution — Toulouse, France
• Local Institution — Villejuif, France
• Local Institution — Otwock, Poland
• Local Institution — Gyeonggi-do, South Korea
• Local Institution — Seoul, South Korea
• Local Institution — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.